Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 May 9. pii: S0140-6736(19)30723-8. doi: 10.1016/S0140-6736(19)30723-8. [Epub ahead of print]

PMID:
31079938
2.

Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.

Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B.

Clin Genitourin Cancer. 2019 Apr 1. pii: S1558-7673(19)30109-0. doi: 10.1016/j.clgc.2019.03.017. [Epub ahead of print]

PMID:
31072748
3.

Optimized management of urolithiasis by coloured stent-stone contrast using dual-energy computed tomography (DECT).

Magistro G, Bregenhorn P, Krauß B, Nörenberg D, D'Anastasi M, Graser A, Weinhold P, Strittmatter F, Stief CG, Staehler M.

BMC Urol. 2019 Apr 30;19(1):29. doi: 10.1186/s12894-019-0459-3.

4.

Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.

Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B, Van Poppel H, Bensalah K; Young Academic Urologists Kidney Cancer Working Group of the European Association of Urology.

Eur Urol Oncol. 2019 Mar;2(2):141-149. doi: 10.1016/j.euo.2018.08.028. Epub 2018 Sep 24. Review.

PMID:
31017089
5.

Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.

Berquist SW, Yim K, Ryan ST, Patel SH, Eldefrawy A, Cotta BH, Bradshaw AW, Meagher MF, Bindayi A, McKay RR, Autorino R, Staehler M, Derweesh IH.

Int J Urol. 2019 May;26(5):532-542. doi: 10.1111/iju.13943. Epub 2019 Apr 3. Review.

PMID:
30943578
6.

Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Scand J Urol. 2019 Mar 25:1-7. doi: 10.1080/21681805.2019.1588919. [Epub ahead of print]

PMID:
30907214
7.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A.

Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.

PMID:
30803729
8.

Adjuvant therapy in renal cell carcinoma: the perspective of urologists.

Spek A, Szabados B, Casuscelli J, Stief C, Staehler M.

Int J Clin Oncol. 2019 Jun;24(6):694-697. doi: 10.1007/s10147-019-01398-x. Epub 2019 Feb 13.

PMID:
30758764
9.

Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.

Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh BS, Lo SS, Muacevic A, Siva S.

J Urol. 2019 Jun;201(6):1097-1104. doi: 10.1097/JU.0000000000000111.

PMID:
30741849
10.

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.

Bergerot CD, Battle D, Bergerot PG, Dizman N, Jonasch E, Hammers HJ, George DJ, Bex A, Ljungberg B, Pal SK, Staehler MD.

Front Oncol. 2019 Jan 22;9:11. doi: 10.3389/fonc.2019.00011. eCollection 2019.

11.

A Return to the Days of Radical Nephrectomy as the "Gold Standard" for Localized Renal Cell Carcinoma? Not So Fast.

Derweesh IH, Staehler M, Uzzo RG.

Eur Urol. 2019 Apr;75(4):546-547. doi: 10.1016/j.eururo.2019.01.003. Epub 2019 Jan 14.

PMID:
30655089
12.

[Follow-up of renal cell carcinoma in a nonmetastatic stage].

Szabados B, Foller S, Schulz GB, Staehler M, Grimm MO, Stief CG, Casuscelli J.

Urologe A. 2019 Jan;58(1):65-76. doi: 10.1007/s00120-018-0823-z. German.

PMID:
30627750
13.

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M.

Clin Genitourin Cancer. 2019 Apr;17(2):e345-e355. doi: 10.1016/j.clgc.2018.07.024. Epub 2018 Aug 11.

PMID:
30528378
14.

Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.

Stenman M, Staehler M, Szabados B, Sandström P, Laurell A, Lindskog M, Harmenberg U.

Acta Oncol. 2019 Mar;58(3):306-312. doi: 10.1080/0284186X.2018.1537505. Epub 2018 Dec 3.

PMID:
30507262
15.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

16.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.

PMID:
30401688
17.

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol. 2019 Feb;75(2):261-264. doi: 10.1016/j.eururo.2018.10.007. Epub 2018 Oct 11.

PMID:
30318330
18.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
19.

Distress in patients with renal cell carcinoma: a curious gap in knowledge.

Bergerot CD, Battle D, Staehler MD, Pal SK.

BJU Int. 2019 Feb;123(2):208-209. doi: 10.1111/bju.14564. Epub 2018 Oct 24. No abstract available.

PMID:
30253048
20.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7. No abstract available.

PMID:
30201510
21.

Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma.

Procházková K, Mírka H, Trávníček I, Pitra T, Kolár J, Roušarová M, Hošek P, Bajcurová K, Ferda J, Staehler M, Brookman May SD, Hes O, Hora M.

Urol Int. 2018;101(4):409-416. doi: 10.1159/000492719. Epub 2018 Sep 10.

PMID:
30199877
22.

A new setup for the quantitative analysis of drying by the use of gas-phase FTIR-spectroscopy.

Scheepers F, Staehler A, Staehler M, Carmo M, Lehnert W, Stolten D.

Rev Sci Instrum. 2018 Aug;89(8):083102. doi: 10.1063/1.5036817.

PMID:
30184627
23.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T.

Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.

PMID:
30177291
24.

Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.

Staehler M, Battle D, Bex A, Hammers H, George D.

Eur Urol. 2018 Dec;74(6):842-843. doi: 10.1016/j.eururo.2018.08.011. Epub 2018 Aug 28. No abstract available.

PMID:
30170873
25.

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Höfler H, Haferkamp A, Geppert CI, Stöhr C, Hartmann A; German Network Of Kidney Cancer.

Hum Pathol. 2019 Jan;83:212-223. doi: 10.1016/j.humpath.2018.08.006. Epub 2018 Aug 17.

PMID:
30121370
26.

Emphysematous pyelonephritis: Case report and literature overview.

Ziegelmüller BK, Szabados B, Spek A, Casuscelli J, Stief C, Staehler M.

Urologia. 2018 Aug;85(3):123-126. doi: 10.1177/0391560317749428. Epub 2018 Mar 26. Review.

PMID:
30117388
27.

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A.

World J Urol. 2018 Dec;36(12):1973-1980. doi: 10.1007/s00345-018-2427-z. Epub 2018 Aug 1.

PMID:
30069581
28.

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.

Goebell PJ, Staehler M, Müller L, Nusch A, Scheffler M, Sauer A, von Verschuer U, Tech S, Kruggel L, Jänicke M, Marschner N; RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma).

Clin Genitourin Cancer. 2018 Dec;16(6):e1101-e1115. doi: 10.1016/j.clgc.2018.06.006. Epub 2018 Jun 27.

29.

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.

Grünwald V, Eberhardt B, Bex A, Flörcken A, Gauler T, Derlin T, Panzica M, Dürr HR, Grötz KA, Giles RH, von Falck C, Graser A, Muacevic A, Staehler M.

Nat Rev Urol. 2018 Aug;15(8):511-521. doi: 10.1038/s41585-018-0034-9. Review.

PMID:
29904105
30.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

PMID:
29773662
31.

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol Focus. 2018 Mar 7. pii: S2405-4569(18)30072-5. doi: 10.1016/j.euf.2018.02.010. [Epub ahead of print]

PMID:
29525381
32.

[Epidemiology and diagnostic assessment of small renal masses].

Ziegelmüller BK, Spek A, Szabados B, Casuscelli J, Clevert DA, Staehler M.

Urologe A. 2018 Mar;57(3):274-279. doi: 10.1007/s00120-018-0585-7. Review. German.

PMID:
29460170
33.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

34.

Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).

Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh B, Correa RJ, Lo SS, Staehler M.

Cancer. 2018 Mar 1;124(5):934-942. doi: 10.1002/cncr.31156. Epub 2017 Dec 20.

35.

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]

PMID:
29223605
36.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

PMID:
28967554
37.

Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

Grande E, Glen H, Aller J, Argenziano G, Lamas MJ, Ruszniewski P, Zamorano JL, Edmonds K, Sarker S, Staehler M, Larkin J.

Expert Opin Drug Saf. 2017 Dec;16(12):1413-1426. doi: 10.1080/14740338.2017.1380624. Epub 2017 Sep 28. Review.

PMID:
28920492
38.

New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?

Escudier B, Staehler M.

Eur Urol. 2018 Jan;73(1):1-3. doi: 10.1016/j.eururo.2017.08.020. Epub 2017 Sep 8.

PMID:
28890247
39.

Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Staehler M, Volpe A, Powles T.

Eur Urol. 2017 May;71(5):719-722. doi: 10.1016/j.eururo.2016.11.034. Epub 2016 Dec 13.

PMID:
27986369
40.

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8. Review.

PMID:
27939075
41.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

42.

Clinical Usage of Different Guidelines in Routine Management, Therapy and Follow-Up of Patients with Renal Cell Cancer in Germany.

Spek A, Szabados B, Ziegelmüller B, Stief C, D'Anastasi M, Staehler M.

Urol Int. 2017;98(2):156-161. doi: 10.1159/000448435. Epub 2016 Oct 18.

PMID:
27750248
43.

Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.

Marschner N, Staehler M, Müller L, Nusch A, Harde J, Koska M, Jänicke M, Goebell PJ; RCC Registry Group.

Clin Genitourin Cancer. 2017 Apr;15(2):e209-e215. doi: 10.1016/j.clgc.2016.08.022. Epub 2016 Sep 8.

44.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

45.

Morphological Characterization of Papillary Renal Cell Carcinoma Type 1, the Efficiency of Its Surgical Treatment.

Procházková K, Staehler M, Trávníček I, Pitra T, Eret V, Ürge T, Eberlová L, Roušarová M, Hošek P, Chudáček Z, Ferda J, Hes O, Hora M.

Urol Int. 2017;98(2):148-155. doi: 10.1159/000448434. Epub 2016 Sep 30.

PMID:
27684070
46.

Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.

Hellbach K, Sterzik A, Sommer W, Karpitschka M, Hummel N, Casuscelli J, Ingrisch M, Schlemmer M, Graser A, Staehler M.

Eur Radiol. 2017 Jun;27(6):2532-2537. doi: 10.1007/s00330-016-4597-7. Epub 2016 Sep 27.

PMID:
27678131
47.

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A.

Eur Urol. 2016 Nov;70(5):705-706. doi: 10.1016/j.eururo.2016.06.009. Epub 2016 Jun 24.

PMID:
27349614
48.

Author Reply.

Ljungberg B, Hedin O, Lundstam S, Warnolf Å, Mandahl Forsberg A, Hjelle KM, Stief CG, Borlinghaus C, Beisland C, Staehler M.

Urology. 2016 Jul;93:122-3. doi: 10.1016/j.urology.2016.01.039. Epub 2016 May 4. No abstract available.

PMID:
27155982
49.

Long-term outcomes after resection of Stage IV cavoatrial tumour extension using deep hypothermic circulatory arrest.

Dashkevich A, Bagaev E, Hagl C, Pichlmaier M, Luehr M, von Dossow V, Stief C, Brenner P, Staehler M.

Eur J Cardiothorac Surg. 2016 Nov;50(5):892-897. Epub 2016 Apr 26.

PMID:
27122607
50.

Nephron Sparing Surgery Associated With Better Survival Than Radical Nephrectomy in Patients Treated for Unforeseen Benign Renal Tumors.

Ljungberg B, Hedin O, Lundstam S, Warnolf Å, Mandahl Forsberg A, Hjelle KM, Stief CG, Borlinghaus C, Beisland C, Staehler M.

Urology. 2016 Jul;93:117-23. doi: 10.1016/j.urology.2016.01.037. Epub 2016 Mar 24.

PMID:
27017902

Supplemental Content

Loading ...
Support Center